Business Overview

CMS has been deeply engaged in the Chinese pharmaceutical market for over 30 years, and has always maintained its patient-centered philosophy. We are dedicated to providing competitive products and services that enable the more effective diagnosis and treatment, whilst enhancing clinical practice to the ultimate benefit of the patient.

We have built three major business segments: cardio-cerebrovascular and gastroenterology, skin health, and ophthalmology. These divisions are run as independent business units, driving growth and cultivating an entrepreneurial spirit, whilst allowing them to benefit from the synergy and sharing of resources, and empowering the divisions to gain leading positions in specialty markets.

We have built a professional foundation driven by medical evidence, and established a mature commercialization platform that is compliant, efficient, resource-sharing and modernized. We possess a professional and highly qualified promotion team with strong execution capability, extensive channel coverage as well as expert resources in specialty fields, and have accumulated rich experience and achievements in market access and brand building, with our major marketed products attaining leading market positions. Meanwhile, we deeply explore the value of our products’ consumer healthcare attributes. Through efficient integration of new retail and new media, we enhance our omni-channel marketing, and systematically deploy across DTP pharmacies, core retail chains, primary healthcare institutions, and e-commerce, continuously generating incremental value in the broad off-hospital market.

We continue to deepen our presence in Southeast Asia and the Middle East. Through our secondary listing in Singapore, we are accelerating the process of industrial internationalization. Leveraging a professional and experienced localized management team, we have established a local operation system covering the full chain of R&D, manufacturing, and commercialization. This enables us to drive the international clinical development and local launch of innovative products, offering one-stop solutions for global pharmaceutical companies expanding into Southeast Asia and the Middle East, thereby forging the Group’s second growth curve.

Based on our deep market insights and mature commercialization capabilities, we are building a global portfolio of differentiated innovative products and efficiently advancing clinical development and commercialization, so as to benefit patients.